1. Cervical Cancer Patient-Derived Orthotopic Xenograft (PDOX) Is Sensitive to Cisplatinum and Resistant to Nab-paclitaxel.
- Author
-
Murakami, Takashi, Murata, Takuya, Kawaguchi, Kei, Kiyuna, Tasuku, Igarashi, Kentaro, Hwang, Ho Kyoung, Hiroshima, Yukihiko, Hozumi, Chihiro, Komatsu, Shin, Kikuchi, Takashi, Lwin, Thinzar M, Delong, Jonathan C, Miyake, Kentaro, Zhang, Yong, Tanaka, Kuniya, Bouvet, Michael, Endo, Itaru, and Hoffman, Robert M
- Subjects
Cancer ,Albumins ,Animals ,Antinematodal Agents ,Cisplatin ,Dose-Response Relationship ,Drug ,Drug Resistance ,Neoplasm ,Female ,Humans ,Mice ,Nude ,Paclitaxel ,Time Factors ,Tumor Burden ,Uterine Cervical Neoplasms ,Xenograft Model Antitumor Assays ,Cervical cancer ,patient-derived othotopic xenograft ,PDOX ,nude mice ,drug response ,cispatinum ,nab-paclitaxel ,Oncology and Carcinogenesis ,Oncology & Carcinogenesis - Abstract
BackgroundCervical cancer is a world-wide problem that requires transformative therapeutic strategies. We have previously developed patient-derived orthotopic xenograft (PDOX) nude-mouse models of this disease. In the present report, we demonstrate that the standard drug, cisplatinum (CDDP), is highly-effective while the new, highly-touted agent, nab-paclitaxel (NAB-PTX) is ineffective.Materials and methodsCervical PDOX tumors were grown on the cervix of nude mice for 4 weeks after surgical orthotopic implantation (SOI). Tumors were treated with CDDP or NAB-PTX.ResultsH&E staining demonstrated that the PDOX tumor recapitulated the original patient tumor. CDDP was highly-effective. One tumor that was treated with CDDP completely regressed. CDDP-treated tumors were smaller (tumor volume ratio: 0.42±0.36) than the control group (tumor volume ratio: 3.47±1.66) (p
- Published
- 2017